HRMY Stock Analysis: Harmony Biosciences Holdings | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.438m USD | 12M Return: 23.8% | US4131971040 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.8M
EPS Trend: 56.3%
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Harmony Biosciences Holdings (HRMY) is a US-based, commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. Its lead and currently approved product is WAKIX (pitolisant), a first-in-class molecule approved to treat excessive daytime sleepiness in adult patients with narcolepsy. Companies operating in the rare-disease pharmaceutical segment typically depend on a small specialty portfolio, often with therapies that command premium pricing and benefit from FDA orphan drug incentives such as extended market exclusivity
- WAKIX net product revenue growth drives quarterly performance
- Prader-Willi Syndrome and Fragile X Phase 3 data readouts approach
- Narcolepsy competition intensifies from Takeda Xywav and emerging therapies
| Net Income: 181.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 2.50 > 1.0 |
| NWC/Revenue: 60.45% < 20% (prev 66.17%; Δ -5.72% < -1%) |
| CFO/TA 0.26 > 3% & CFO 355.1m > Net Income 181.3m |
| Net Debt (-513.8m) to EBITDA (276.4m): -1.86 < 3 |
| Current Ratio: 3.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.8m) vs 12m ago 0.59% < -2% |
| Gross Margin: 75.42% > 18% (prev 78.34%; Δ -2.92% > 0.5%) |
| Asset Turnover: 77.38% > 50% (prev 69.72%; Δ 7.65% > 0%) |
| Interest Coverage Ratio: 18.62 > 6 (EBIT TTM 251.1m / Interest Expense TTM 13.5m) |
| A: 0.42 (Total Current Assets 814.3m - Total Current Liabilities 234.1m) / Total Assets 1.37b |
| B: 0.20 (Retained Earnings 268.8m / Total Assets 1.37b) |
| C: 0.20 (EBIT TTM 251.1m / Avg Total Assets 1.24b) |
| D: 2.67 (Book Value of Equity 999.2m / Total Liabilities 373.8m) |
| Altman-Z'' = 7.58 = AAA |
| DSRI: 0.96 (Receivables 111.0m/93.0m, Revenue 959.9m/772.5m) |
| GMI: 1.04 (GM 78.34% / 75.42%) |
| AQI: 1.08 (AQ_t 0.40 / AQ_t-1 0.37) |
| SGI: 1.24 (Revenue 959.9m / 772.5m) |
| TATA: -0.13 (NI 181.3m - CFO 355.1m) / TA 1.37b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of September 11, 2026, the stock is trading at USD 41.10 with a total of 736,799 shares traded. Over the past week, the price has changed by -4.11%, over one month by +5.38%, over three months by +15.84% and over the past year by +23.76%.
Current recommended Stop Loss: 38.70 (which is 5.8% or 1.8 ATR below the current price).
Harmony Biosciences Holdings has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy HRMY.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 47.4 | 15.2% |
P/E Trailing = 13.8609
P/E Forward = 10.2459
P/S = 2.5396
P/B = 2.4041
Revenue TTM = 959.9m USD
EBIT TTM = 251.1m USD
EBITDA TTM = 276.4m USD
Long Term Debt = 134.0m USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 154.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -513.8m USD (calculated: Debt 154.0m - CCE 667.8m)
Enterprise Value = 1.92b USD (2.44b + Debt 154.0m - CCE 667.8m)
Interest Coverage Ratio = 18.62 (Ebit TTM 251.1m / Interest Expense TTM 13.5m)
EV/FCF = 5.42x (Enterprise Value 1.92b / FCF TTM 354.9m)
FCF Yield = 18.45% (FCF TTM 354.9m / Enterprise Value 1.92b)
FCF Margin = 36.97% (FCF TTM 354.9m / Revenue TTM 959.9m)
Net Margin = 18.88% (Net Income TTM 181.3m / Revenue TTM 959.9m)
Gross Margin = 75.42% ((Revenue TTM 959.9m - Cost of Revenue TTM 235.9m) / Revenue TTM)
Gross Margin QoQ = 75.81% (prev 79.33%)
Tobins Q-Ratio = 1.40 (Enterprise Value 1.92b / Total Assets 1.37b)
Interest Expense / Debt = 8.76% (Interest Expense 13.5m / Debt 154.0m)
Taxrate = 24.85% (59.9m / 241.2m)
NOPAT = 188.7m (EBIT 251.1m * (1 - 24.85%))
Current Ratio = 3.48 (Total Current Assets 814.3m / Total Current Liabilities 234.1m)
Debt / Equity = 0.15 (Debt 154.0m / totalStockholderEquity, last quarter 999.2m)
Debt / EBITDA = -1.86 (Net Debt -513.8m / EBITDA 276.4m)
Debt / FCF = -1.45 (Net Debt -513.8m / FCF TTM 354.9m)
Total Stockholder Equity = 903.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.61% (Net Income 181.3m / Total Assets 1.37b)
RoE = 20.06% (Net Income TTM 181.3m / Total Stockholder Equity 903.7m)
RoCE = 24.19% (EBIT 251.1m / Capital Employed (Equity 903.7m + L.T.Debt 134.0m))
RoIC = 16.98% (NOPAT 188.7m / Invested Capital 1.11b)
WACC = 7.56% (E(2.44b)/V(2.59b) * Re(7.62%) + D(154.0m)/V(2.59b) * Rd(8.76%) * (1-Tc(0.25)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.96 | Cagr: 0.90%
[DCF] Terminal Value 77.97% ; FCFF base≈316.4m ; Y1≈362.7m ; Y5≈533.8m
[DCF] Fair Price = 146.8 (EV 8.03b - Net Debt -513.8m = Equity 8.55b / Shares 58.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 56.32 | EPS CAGR: 7.07% | SUE: 0.81 | # QB: 0
Revenue Correlation: 99.79 | Revenue CAGR: 21.90% | SUE: 1.23 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.47 | Chg30d=+19.88% | Revisions=+50% | Analysts=2
EPS current Year (2026-12-31): EPS=5.22 | Chg30d=+16.09% | Revisions=+17% | GrowthEPS=+45.1% | GrowthRev=+18.7%
EPS next Year (2027-12-31): EPS=6.69 | Chg30d=+11.08% | Revisions=-17% | GrowthEPS=+28.1% | GrowthRev=+12.6%
[Analyst] Revisions Ratio: +25% (up=6, down=3)